Thiazolidinediones reduce endothelial expression of receptors for advanced glycation end products.
Marx
Nikolaus
N
Department of Internal Medicine II-Cardiology, University of Ulm, Robert-Koch-Str. 8, D-89081 Ulm, Germany. nikolaus.marx@medizin.uni-ulm.de
Walcher
Daniel
D
Ivanova
Nina
N
Rautzenberg
Kirstin
K
Jung
Annelie
A
Friedl
Reinhard
R
Hombach
Vinzenz
V
de Caterina
Raffaele
R
Basta
Giuseppina
G
Wautier
Marie-Paule
MP
Wautiers
Jean-Luc
JL
D002478:Cells, Cultured; D004730:Endothelium, Vascular / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D016328:NF-kappa B / Q000378:metabolism; D000077205:Pioglitazone; D011401:Promoter Regions, Genetic / Q000187:drug effects / Q000235:genetics; D012333:RNA, Messenger / Q000235:genetics; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic / Q000187:drug effects / Q000235:genetics*; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000494:pharmacology*; D014158:Transcription, Genetic / Q000187:drug effects*; D014471:Umbilical Veins
D007004:Hypoglycemic Agents; D016328:NF-kappa B; D012333:RNA, Messenger; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D000077205:Pioglitazone